AKT1 and Hepatic fibrosis: The anti-liver fibrotic mechanism of LLAAF may be related to the downregulation of Jak-STAT and PI3K-Akt-FoxO activity, indicating that LLAAF should be further evaluated as a novel therapeutic formula to control liver fibrosis.